Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

C. Genovese, M.; Covarrubias, A.; Léon, G.; Mysler, Eduardo; Keiserman, M.; Valente, R.; Nash, Peter; A. Simon‐Campos, J.; Porawska, W.; Box, Jeffrey; W. Legerton, Clarence; L Nasonov, E; Durez, Patrick; Aranda, R.; Pappu, R.; Delaet, I.; Teng, J.; Alten, Rieke

doi:10.1002/art.30463

Public

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

Published in Arthritis & Rheumatism • May 25, 2011

Authors:

M. C. Genovese

A. Covarrubias

G. Léon

Abstract

OBJECTIVE: To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept. METHODS: In this phase IIIb double-blind, double-dummy, 6-month study, patients with rheumatoid arthritis (RA) and inadequate responses to methotrexate were randomized to receive 125 mg SC abatacept on...

Subject

Abatacept

Medicine

Rheumatoid arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!